Semax for neurotrophic support Semax, a synthetic heptapeptide derived from ACTH(4-10), upregulates BDNF expression in brain regions relevant to neurological function
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test reveals predispositions in GIPR (rs1800437), GLP1R (rs6923761), and related metabolic pathways that may contextualize tolerability risk
Funnel plots were created to assess the publication bias in this meta-analysis
Clinical studies have also shown that semaglutide may reduce the risk of major adverse cardiovascular events in high-risk patients, including cardiovascular death, heart attacks and strokes